Commentary: Old Data Provide New Insights Into the Therapeutic Benefit of Adjuvant Chemotherapy in Non-Small Cell Lung Cancer

Semin Thorac Cardiovasc Surg. 2024;36(2):271-272. doi: 10.1053/j.semtcvs.2022.11.006. Epub 2022 Nov 16.

Authors

Kyle G Mitchell¹, Mara B Antonoff²

Affiliations

¹ Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas.
² Department of Thoracic and Cardiovascular Surgery, University of Texas MD Anderson Cancer Center, Houston, Texas.. Electronic address: [email protected].

PMID: 36400354
DOI: 10.1053/j.semtcvs.2022.11.006

No abstract available

Publication types

Editorial

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / adverse effects
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / mortality
Carcinoma, Non-Small-Cell Lung* / pathology
Chemotherapy, Adjuvant
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / mortality
Lung Neoplasms* / pathology
Pneumonectomy / adverse effects
Pneumonectomy / mortality
Risk Factors
Treatment Outcome